Consortium for the Study of Adverse Blood Transfusion Reactions
China is a large country with a population of more than one billion people, and there is a large demand for clinical blood transfusion every year. A unified blood transfusion early warning reporting system and monitoring system have not been established yet, and there is a lack of authoritative statistics on adverse reactions to blood transfusion, and the whole chain of blood transfusion is not effectively monitored. As a special drug, blood is inevitably subject to adverse blood transfusion reactions while saving patients' lives, and the adverse reactions are more frequent and serious than those of common drugs.
China is a large country with a population of more than one billion people, and there is a large demand for clinical blood transfusion every year. A unified blood transfusion early warning reporting system and monitoring system have not been established yet, and there is a lack of authoritative statistics on adverse reactions to blood transfusion, and the whole chain of blood transfusion is not effectively monitored. As a special drug, blood is inevitably subject to adverse blood transfusion reactions while saving patients' lives, and the adverse reactions are more frequent and serious than those of common drugs.
In 2017, the World Health Organization (WHO) called for a 50% reduction in serious and avoidable drug-related injuries in all countries in the next five years. This is a global initiative. To this end, countries are taking measures to carry out research on adverse drug reactions, reduce and prevent adverse drug reactions, and improve patient safety. In response to the WHO's call to promote the building of a healthy China and improve people's health, according to the "Healthy China 2030" planning outline, the Chinese Academy of Medical Sciences Peking Union Medical College Hospital, Chinese Academy of Medical Sciences Fuwai Hospital, Chinese Academy of Medical Sciences Cancer Hospital, Chinese Academy of Medical Sciences The expert team of the Institute, the Transfusion Institute of the Chinese Academy of Medical Sciences and the Beijing Red Cross Blood Center jointly undertook the first batch of "Medical and Health Innovation Project"-the mechanism and intervention projects of adverse transfusion reactions。
After two years of concerted efforts, the team established the basic framework for the study of adverse blood transfusion reactions, optimized the overall design of the project, initially established the grading, classification and intervention guidelines for the differential diagnosis of adverse blood transfusion reactions, developed the reporting system for adverse blood transfusion reactions, and formulated the collection protocols for specimens, and the overall design of the project was recognized by domestic and international colleagues.
The alliance integrates domestic and foreign advantages, highlights its characteristics, stands at the forefront, and focuses on the research and intervention of adverse transfusion reactions. For the purpose of reducing adverse blood transfusion reactions, starting from improving blood safety and reducing irrational blood use, focusing on the main factors that affect the safety and effectiveness of blood transfusion, carrying out basic, clinical and applied research to improve the efficacy of blood transfusion, reduce medical costs, and prevent adverse blood transfusion reactions Early warning system construction provides scientific support.
The members of each alliance should adhere to the purpose of "jointness, collaboration, sharing and win-win", strengthen the contact and cooperation between the teams, give full play to the clinical and scientific research advantages of each alliance, gather the strengths of strength, integrate each other, complement each other, and jointly improve blood transfusion The ability and level of differential diagnosis, classification, classification, treatment and prevention of adverse reactions, reduce the incidence of adverse reactions in blood transfusion, and improve patient safety.
